Contact Us
EH
Pipeline

The company boasts a rich research and development pipeline in the oncology field, and has also made extensive layouts in the fields of metabolism and cardiovascular diseases, immune and respiratory system diseases, as well as neuroscience.

R&D achievements
*Data as of May 1, 2025
CNS
IND
Phase I
Phase II
Phase III
NDA/Marketed
RIA (Respiratory, Inflammatory and Autoimmune)
IND
Phase I
Phase II
Phase III
NDA/Marketed
Oncology
IND
  • PARP1

    PARP1

    Late-stage solid tumors, breast cancer brain metastases, and IDH1-mutant intracranial gliomas

Phase I
Phase II
Phase III
NDA/Marketed
CMDs
IND
Phase I
Phase II
Phase III
NDA/Marketed